Altogether, the anti‐metastatic effect of fibroblastic FAK inhibition appears to be linked to reduced fibroblast migration and invasive abilities, and to ECM remodelling leading to a decrease of integrin activation in tumour cells. The gene discussed is PTK2; the disease is neoplasm.